Abstract：
BACKGROUND: Retroperitoneal liposarcomas are locally aggressive and frequently recur following complete surgical resection. Palbociclib, a cyclin-dependent kinase (CDK) 4/CDK6 inhibitor, is effective in the treatment of metastatic or unresectable liposarcoma.
OBJECTIVE: The purpose of this study was to describe our initial experience using adjuvant palbociclib to delay recurrence.
METHODS: Patients with resected RPS were identified from a prospectively maintained institutional database. In 2017, we began offering adjuvant palbociclib to patients following complete gross resection. Treatment interval, defined as the time between surgical resection and re-resection or change in systemic therapy, was compared between patients selected for adjuvant palbociclib or observation.
RESULTS: Between 2017 and 2020, 12 patients underwent a total of 14 operations (14 patient cases) and were selected for adjuvant palbociclib for recurrence prevention. These patients were compared with 14 patients who, since 2010, underwent a total of 20 operations (20 patient cases) and were selected for observation. Histology was primarily dedifferentiated liposarcoma for both groups (observation: 70% [14/20]; adjuvant palbociclib: 64% [9/14]). All patients underwent complete gross resection. Neither age, number of previous surgeries, histologic grade, or Eastern Cooperative Oncology Group (ECOG) performance status differed between groups (p > 0.05 for all). Patients selected for adjuvant palbociclib experienced a longer treatment interval than those selected for observation, although it did not reach statistical significance (20.5 months vs. 13.1 months, p = 0.08, log rank).
CONCLUSIONS: Adjuvant palbociclib may be associated with a prolonged interval between liposarcoma resection and the need for re-resection or other systemic therapy. Palbociclib may be effective in delaying liposarcoma recurrence, and its use for this indication warrants prospective study.
OBJECTIVE: The purpose of this study was to describe our initial experience using adjuvant palbociclib to delay recurrence.
METHODS: Patients with resected RPS were identified from a prospectively maintained institutional database. In 2017, we began offering adjuvant palbociclib to patients following complete gross resection. Treatment interval, defined as the time between surgical resection and re-resection or change in systemic therapy, was compared between patients selected for adjuvant palbociclib or observation.
RESULTS: Between 2017 and 2020, 12 patients underwent a total of 14 operations (14 patient cases) and were selected for adjuvant palbociclib for recurrence prevention. These patients were compared with 14 patients who, since 2010, underwent a total of 20 operations (20 patient cases) and were selected for observation. Histology was primarily dedifferentiated liposarcoma for both groups (observation: 70% [14/20]; adjuvant palbociclib: 64% [9/14]). All patients underwent complete gross resection. Neither age, number of previous surgeries, histologic grade, or Eastern Cooperative Oncology Group (ECOG) performance status differed between groups (p > 0.05 for all). Patients selected for adjuvant palbociclib experienced a longer treatment interval than those selected for observation, although it did not reach statistical significance (20.5 months vs. 13.1 months, p = 0.08, log rank).
CONCLUSIONS: Adjuvant palbociclib may be associated with a prolonged interval between liposarcoma resection and the need for re-resection or other systemic therapy. Palbociclib may be effective in delaying liposarcoma recurrence, and its use for this indication warrants prospective study.
摘要：
背景：腹膜后脂肪肉瘤是局部侵袭性的，在完全手术切除后经常复发。Palbociclib,细胞周期蛋白依赖性激酶（CDK）4/CDK6抑制剂，可有效治疗转移性或不可切除的脂肪肉瘤。
目的：本研究的目的是描述我们使用palbociclib辅助治疗延迟复发的初步经验。
方法：从前瞻性维护的机构数据库中确定RPS切除患者。2017年，我们开始为完全切除后的患者提供palbociclib辅助治疗。治疗间隔,定义为手术切除和再切除或全身治疗改变之间的时间，在选择palbociclib辅助治疗或观察的患者之间进行比较。
结果：在2017年至2020年之间，12例患者共接受了14次手术（14例患者），并选择了palbociclib辅助预防复发。这些患者与14名患者进行了比较，自2010年以来,共接受了20例手术(20例患者),并选择进行观察.组织学上两组主要是去分化脂肪肉瘤(观察:70%[14/20];palbociclib佐剂:64%[9/14])。所有患者均接受完全大体切除。无论是年龄，以前的手术数量，组织学分级,或东部肿瘤协作组（ECOG）的表现状态在组间存在差异（均p>0.05）。选择palbociclib辅助治疗的患者比选择观察的患者经历了更长的治疗间隔，虽然没有达到统计学意义(20.5个月vs.13.1个月，p=0.08,对数秩)。
结论：辅助palbociclib可能与脂肪肉瘤切除和需要再次切除或其他全身治疗之间的间隔时间延长有关。Palbociclib可有效延缓脂肪肉瘤复发，及其在这一适应症中的应用值得前瞻性研究。
目的：本研究的目的是描述我们使用palbociclib辅助治疗延迟复发的初步经验。
方法：从前瞻性维护的机构数据库中确定RPS切除患者。2017年，我们开始为完全切除后的患者提供palbociclib辅助治疗。治疗间隔,定义为手术切除和再切除或全身治疗改变之间的时间，在选择palbociclib辅助治疗或观察的患者之间进行比较。
结果：在2017年至2020年之间，12例患者共接受了14次手术（14例患者），并选择了palbociclib辅助预防复发。这些患者与14名患者进行了比较，自2010年以来,共接受了20例手术(20例患者),并选择进行观察.组织学上两组主要是去分化脂肪肉瘤(观察:70%[14/20];palbociclib佐剂:64%[9/14])。所有患者均接受完全大体切除。无论是年龄，以前的手术数量，组织学分级,或东部肿瘤协作组（ECOG）的表现状态在组间存在差异（均p>0.05）。选择palbociclib辅助治疗的患者比选择观察的患者经历了更长的治疗间隔，虽然没有达到统计学意义(20.5个月vs.13.1个月，p=0.08,对数秩)。
结论：辅助palbociclib可能与脂肪肉瘤切除和需要再次切除或其他全身治疗之间的间隔时间延长有关。Palbociclib可有效延缓脂肪肉瘤复发，及其在这一适应症中的应用值得前瞻性研究。
